- Home
- BEDU vs KPTI Comparison
BEDU vs KPTI Comparison
Compare BEDU & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEDU
- KPTI
- Stock Information
- Founded
- BEDU 1994
- KPTI 2008
- Country
- BEDU United Kingdom
- KPTI United States
- Employees
- BEDU N/A
- KPTI N/A
- Industry
- BEDU Other Consumer Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- BEDU Real Estate
- KPTI Health Care
- Exchange
- BEDU Nasdaq
- KPTI Nasdaq
- Market Cap
- BEDU 47.7M
- KPTI 44.5M
- IPO Year
- BEDU 2017
- KPTI 2013
- Fundamental
- Price
- BEDU N/A
- KPTI $4.39
- Analyst Decision
- BEDU
- KPTI Buy
- Analyst Count
- BEDU 0
- KPTI 6
- Target Price
- BEDU N/A
- KPTI $48.50
- AVG Volume (30 Days)
- BEDU 3.4K
- KPTI 53.3K
- Earning Date
- BEDU 08-01-2025
- KPTI 08-05-2025
- Dividend Yield
- BEDU N/A
- KPTI N/A
- EPS Growth
- BEDU N/A
- KPTI N/A
- EPS
- BEDU N/A
- KPTI N/A
- Revenue
- BEDU $224,321,752.00
- KPTI $142,126,000.00
- Revenue This Year
- BEDU N/A
- KPTI $2.09
- Revenue Next Year
- BEDU N/A
- KPTI $12.90
- P/E Ratio
- BEDU N/A
- KPTI N/A
- Revenue Growth
- BEDU N/A
- KPTI 1.19
- 52 Week Low
- BEDU $1.35
- KPTI $3.51
- 52 Week High
- BEDU $2.41
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- BEDU 54.28
- KPTI 45.76
- Support Level
- BEDU $1.70
- KPTI $4.12
- Resistance Level
- BEDU $1.80
- KPTI $4.85
- Average True Range (ATR)
- BEDU 0.04
- KPTI 0.31
- MACD
- BEDU -0.00
- KPTI 0.04
- Stochastic Oscillator
- BEDU 53.57
- KPTI 36.99
About BEDU Bright Scholar Education Holdings Limited each representing four
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom (the UK) and the United States (the U.S.) Kingdom. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.